References
- Van Parijs, L. and A. K. Abbas. 1998. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280: 243-248. https://doi.org/10.1126/science.280.5361.243
- Chen, L. and D. B. Flies. 2013. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13: 227-242. https://doi.org/10.1038/nri3405
- Pardoll, D. M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12: 252-264. https://doi.org/10.1038/nrc3239
- Saito, T., T. Yokosuka, and A. Hashimoto-Tane. 2010. Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters. FEBS Lett. 584: 4865-4871. https://doi.org/10.1016/j.febslet.2010.11.036
- Greenwald, R. J., G. J. Freeman, and A. H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23: 515-548. https://doi.org/10.1146/annurev.immunol.23.021704.115611
- Isakov, N. and A. Altman. 2012. PKC-theta-mediated signal delivery from the TCR/CD28 surface receptors. Front. Immunol. 3: 273.
- Rudd, C. E. and H. Schneider. 2003. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat. Rev. Immunol. 3: 544-556. https://doi.org/10.1038/nri1131
- Viola, A. and A. Lanzavecchia. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273: 104-106. https://doi.org/10.1126/science.273.5271.104
- Boise, L. H., A. J. Minn, P. J. Noel, C. H. June, M. A. Accavitti, T. Lindsten, and C. B. Thompson. 1995. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3: 87-98. https://doi.org/10.1016/1074-7613(95)90161-2
- Rulifson, I. C., A. I. Sperling, P. E. Fields, F. W. Fitch, and J. A. Bluestone. 1997. CD28 costimulation promotes the production of Th2 cytokines. J. Immunol. 158: 658-665.
- Zhang, R., A. Huynh, G. Whitcher, J. Chang, J. S. Maltzman, and L. A. Turka. 2013. An obligate cell-intrinsic function for CD28 in Tregs. J. Clin. Invest. 123: 580-593.
- Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1: 405-413. https://doi.org/10.1016/1074-7613(94)90071-X
- Salama, A. K. and F. S. Hodi. 2011. Cytotoxic T-lymphocyte- associated antigen-4. Clin. Cancer Res. 17: 4622-4628. https://doi.org/10.1158/1078-0432.CCR-10-2232
- Qureshi, O. S., Y. Zheng, K. Nakamura, K. Attridge, C. Manzotti, E. M. Schmidt, J. Baker, L. E. Jeffery, S. Kaur, Z. Briggs, T. Z. Hou, C. E. Futter, G. Anderson, L. S. Walker, and D. M. Sansom. 2011. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332: 600-603. https://doi.org/10.1126/science.1202947
- Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061. https://doi.org/10.1126/science.1079490
- Fontenot, J. D., M. A. Gavin, and A. Y. Rudensky. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4: 330-336. https://doi.org/10.1038/ni904
- Paust, S., L. Lu, N. McCarty, and H. Cantor. 2004. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc. Natl. Acad. Sci. USA 101: 10398- 10403. https://doi.org/10.1073/pnas.0403342101
- Grohmann, U., C. Orabona, F. Fallarino, C. Vacca, F. Calcinaro, A. Falorni, P. Candeloro, M. L. Belladonna, R. Bianchi, M. C. Fioretti, and P. Puccetti. 2002. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3: 1097-1101. https://doi.org/10.1038/ni846
- Fallarino, F., U. Grohmann, K. W. Hwang, C. Orabona, C. Vacca, R. Bianchi, M. L. Belladonna, M. C. Fioretti, M. L. Alegre, and P. Puccetti. 2003. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4: 1206-1212. https://doi.org/10.1038/ni1003
- Munn, D. H., M. D. Sharma, and A. L. Mellor. 2004. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 172: 4100-4110. https://doi.org/10.4049/jimmunol.172.7.4100
- Keir, M. E., M. J. Butte, G. J. Freeman, and A. H. Sharpe. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26: 677-704. https://doi.org/10.1146/annurev.immunol.26.021607.090331
- Butte, M. J., M. E. Keir, T. B. Phamduy, A. H. Sharpe, and G. J. Freeman. 2007. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27: 111-122. https://doi.org/10.1016/j.immuni.2007.05.016
- Shlapatska, L. M., S. V. Mikhalap, A. G. Berdova, O. M. Zelensky, T. J. Yun, K. E. Nichols, E. A. Clark, and S. P. Sidorenko. 2001. CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. J. Immunol. 166: 5480-5487. https://doi.org/10.4049/jimmunol.166.9.5480
- Agata, Y., A. Kawasaki, H. Nishimura, Y. Ishida, T. Tsubata, H. Yagita, and T. Honjo. 1996. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8: 765-772. https://doi.org/10.1093/intimm/8.5.765
- Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, V. A. Lennon, E. Celis, and L. Chen. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8: 793-800. https://doi.org/10.1038/nm730
- Blank, C., I. Brown, A. C. Peterson, M. Spiotto, Y. Iwai, T. Honjo, and T. F. Gajewski. 2004. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 64: 1140-1145. https://doi.org/10.1158/0008-5472.CAN-03-3259
- Taube, J. M., R. A. Anders, G. D. Young, H. Xu, R. Sharma, T. L. McMiller, S. Chen, A. P. Klein, D. M. Pardoll, S. L. Topalian, and L. Chen. 2012. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4: 127ra137.
- Thompson, R. H., S. M. Kuntz, B. C. Leibovich, H. Dong, C. M. Lohse, W. S. Webster, S. Sengupta, I. Frank, A. S. Parker, H. Zincke, M. L. Blute, T. J. Sebo, J. C. Cheville, and E. D. Kwon. 2006. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow- up. Cancer Res. 66: 3381-3385. https://doi.org/10.1158/0008-5472.CAN-05-4303
- Boland, J. M., E. D. Kwon, S. M. HH. Tang, P. Yang, and M. C. Aubry. 2013. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin. Lung Cancer 14: 157-163. https://doi.org/10.1016/j.cllc.2012.05.006
- Mu, C. Y., J. A. Huang, Y. Chen, C. Chen, and X. G. Zhang. 2011. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med. Oncol. 28: 682-688. https://doi.org/10.1007/s12032-010-9515-2
- Wang, L., Q. Ma, X. Chen, K. Guo, J. Li, and M. Zhang. 2010. Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma. World J. Surg. 34: 1059-1065. https://doi.org/10.1007/s00268-010-0448-x
- Nakanishi, J., Y. Wada, K. Matsumoto, M. Azuma, K. Kikuchi, and S. Ueda. 2007. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol. Immunother. 56: 1173-1182. https://doi.org/10.1007/s00262-006-0266-z
- Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687. https://doi.org/10.1038/nature04444
- Day, C. L., D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, Z. Mncube, J. Duraiswamy, B. Zhu, Q. Eichbaum, M. Altfeld, E. J. Wherry, H. M. Coovadia, P. J. Goulder, P. Klenerman, R. Ahmed, G. J. Freeman, and B. D. Walker. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354. https://doi.org/10.1038/nature05115
- West, E. E., H. T. Jin, A. U. Rasheed, P. Penaloza-Macmaster, S. J. Ha, W. G. Tan, B. Youngblood, G. J. Freeman, K. A. Smith, and R. Ahmed. 2013. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J. Clin. Invest. 123: 2604-2615. https://doi.org/10.1172/JCI67008
- Shin, T., K. Yoshimura, T. Shin, E. B. Crafton, H. Tsuchiya, F. Housseau, H. Koseki, R. D. Schulick, L. Chen, and D. M. Pardoll. 2005. In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J. Exp. Med. 201: 1531-1541. https://doi.org/10.1084/jem.20050072
- Dong, H., G. Zhu, K. Tamada, and L. Chen. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5: 1365- 1369. https://doi.org/10.1038/70932
- Francisco, L. M., V. H. Salinas, K. E. Brown, V. K. Vanguri, G. J. Freeman, V. K. Kuchroo, and A. H. Sharpe. 2009. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206: 3015-3029. https://doi.org/10.1084/jem.20090847
- Gajewski, T. F., J. Louahed, and V. G. Brichard. 2010. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 16: 399-403. https://doi.org/10.1097/PPO.0b013e3181eacbd8
- Brahmer, J. R., C. G. Drake, I. Wollner, J. D. Powderly, J. Picus, W. H. Sharfman, E. Stankevich, A. Pons, T. M. Salay, T. L. McMiller, M. M. Gilson, C. Wang, M. Selby, J. M. Taube, R. Anders, L. Chen, A. J. Korman, D. M. Pardoll, I. Lowy, and S. L. Topalian. 2010. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28: 3167-3175. https://doi.org/10.1200/JCO.2009.26.7609
- van Elsas, A., A. A. Hurwitz, and J. P. Allison. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/ macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190: 355-366. https://doi.org/10.1084/jem.190.3.355
- Li, B., M. VanRoey, C. Wang, T. H. Chen, A. Korman, and K. Jooss. 2009. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin. Cancer Res. 15: 1623- 1634. https://doi.org/10.1158/1078-0432.CCR-08-1825
- Swallow, M. M., J. J. Wallin, and W. C. Sha. 1999. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity 11: 423-432. https://doi.org/10.1016/S1074-7613(00)80117-X
- Ling, V., P. W. Wu, H. F. Finnerty, K. M. Bean, V. Spaulding, L. A. Fouser, J. P. Leonard, S. E. Hunter, R. Zollner, J. L. Thomas, J. S. Miyashiro, K. A. Jacobs, and M. Collins. 2000. Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor. J. Immunol. 164: 1653-1657. https://doi.org/10.4049/jimmunol.164.4.1653
- Yoshinaga, S. K., J. S. Whoriskey, S. D. Khare, U. Sarmiento, J. Guo, T. Horan, G. Shih, M. Zhang, M. A. Coccia, T. Kohno, A. Tafuri-Bladt, D. Brankow, P. Campbell, D. Chang, L. Chiu, T. Dai, G. Duncan, G. S. Elliott, A. Hui, S. M. McCabe, S. Scully, A. Shahinian, C. L. Shaklee, G. Van, T. W. Mak, and G. Senaldi. 1999. T-cell co-stimulation through B7RP-1 and ICOS. Nature 402: 827-832. https://doi.org/10.1038/45582
- Aicher, A., M. Hayden-Ledbetter, W. A. Brady, A. Pezzutto, G. Richter, D. Magaletti, S. Buckwalter, J. A. Ledbetter, and E. A. Clark. 2000. Characterization of human inducible costimulator ligand expression and function. J. Immunol. 164: 4689-4696. https://doi.org/10.4049/jimmunol.164.9.4689
- Nakazawa, A., I. Dotan, J. Brimnes, M. Allez, L. Shao, F. Tsushima, M. Azuma, and L. Mayer. 2004. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology 126: 1347-1357. https://doi.org/10.1053/j.gastro.2004.02.004
- Wiendl, H., M. Mitsdoerffer, D. Schneider, A. Melms, H. Lochmuller, R. Hohlfeld, and M. Weller. 2003. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 126: 1026-1035. https://doi.org/10.1093/brain/awg114
- Brodie, D., A. V. Collins, A. Iaboni, J. A. Fennelly, L. M. Sparks, X. N. Xu, P. A. van der Merwe, and S. J. Davis. 2000. LICOS, a primordial costimulatory ligand? Curr. Biol. 10: 333-336. https://doi.org/10.1016/S0960-9822(00)00383-3
- Wang, S., G. Zhu, A. I. Chapoval, H. Dong, K. Tamada, J. Ni, and L. Chen. 2000. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood 96: 2808-2813.
- Beier, K. C., A. Hutloff, A. M. Dittrich, C. Heuck, A. Rauch, K. Buchner, B. Ludewig, H. D. Ochs, H. W. Mages, and R. A. Kroczek. 2000. Induction, binding specificity and function of human ICOS. Eur. J. Immunol. 30: 3707-3717. https://doi.org/10.1002/1521-4141(200012)30:12<3707::AID-IMMU3707>3.0.CO;2-Q
- Mages, H. W., A. Hutloff, C. Heuck, K. Buchner, H. Himmelbauer, F. Oliveri, and R. A. Kroczek. 2000. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand. Eur. J. Immunol. 30: 1040-1047. https://doi.org/10.1002/(SICI)1521-4141(200004)30:4<1040::AID-IMMU1040>3.0.CO;2-6
- Yoshinaga, S. K., M. Zhang, J. Pistillo, T. Horan, S. D. Khare, K. Miner, M. Sonnenberg, T. Boone, D. Brankow, T. Dai, J. Delaney, H. Han, A. Hui, T. Kohno, R. Manoukian, J. S. Whoriskey, and M. A. Coccia. 2000. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. Int. Immunol. 12: 1439-1447. https://doi.org/10.1093/intimm/12.10.1439
- Coyle, A. J., S. Lehar, C. Lloyd, J. Tian, T. Delaney, S. Manning, T. Nguyen, T. Burwell, H. Schneider, J. A. Gonzalo, M. Gosselin, L. R. Owen, C. E. Rudd, and J. C. Gutierrez-Ramos. 2000. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 13: 95-105. https://doi.org/10.1016/S1074-7613(00)00011-X
- Sharpe, A. H. and G. J. Freeman. 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2: 116-126. https://doi.org/10.1038/nri727
- Kopf, M., A. J. Coyle, N. Schmitz, M. Barner, A. Oxenius, A. Gallimore, J. C. Gutierrez-Ramos, and M. F. Bachmann. 2000. Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection. J. Exp. Med. 192: 53-61. https://doi.org/10.1084/jem.192.1.53
- Sperling, A. I. 2001. ICOS costimulation: is it the key to selective immunotherapy? Clin. Immunol. 100: 261-262. https://doi.org/10.1006/clim.2001.5084
- Akbari, O., G. J. Freeman, E. H. Meyer, E. A. Greenfield, T. T. Chang, A. H. Sharpe, G. Berry, R. H. DeKruyff, and D. T. Umetsu. 2002. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat. Med. 8: 1024-1032. https://doi.org/10.1038/nm745
- Riella, L. V., S. Dada, L. Chabtini, B. Smith, L. Huang, P. Dakle, B. Mfarrej, F. D'Addio, L. T. Adams, N. Kochupurakkal, A. Vergani, P. Fiorina, A. L. Mellor, A. H. Sharpe, H. Yagita, and I. Guleria. 2013. B7h (ICOS-L) maintains tolerance at the fetomaternal interface. Am. J. Pathol. 182: 2204-2213. https://doi.org/10.1016/j.ajpath.2013.02.014
- Hu, Y. L., D. P. Metz, J. Chung, G. Siu, and M. Zhang. 2009. B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells. J. Immunol. 182: 1421-1428. https://doi.org/10.4049/jimmunol.182.3.1421
- Yao, S., Y. Zhu, G. Zhu, M. Augustine, L. Zheng, D. J. Goode, M. Broadwater, W. Ruff, S. Flies, H. Xu, D. Flies, L. Luo, S. Wang, and L. Chen. 2011. B7-h2 is a costimulatory ligand for CD28 in human. Immunity 34: 729-740. https://doi.org/10.1016/j.immuni.2011.03.014
- Chapoval, A. I., J. Ni, J. S. Lau, R. A. Wilcox, D. B. Flies, D. Liu, H. Dong, G. L. Sica, G. Zhu, K. Tamada, and L. Chen. 2001. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat. Immunol. 2: 269-274. https://doi.org/10.1038/85339
- Sun, M., S. Richards, D. V. Prasad, X. M. Mai, A. Rudensky, and C. Dong. 2002. Characterization of mouse and human B7-H3 genes. J. Immunol. 168: 6294-6297. https://doi.org/10.4049/jimmunol.168.12.6294
- Steinberger, P., O. Majdic, S. V. Derdak, K. Pfistershammer, S. Kirchberger, C. Klauser, G. Zlabinger, W. F. Pickl, J. Stockl, and W. Knapp. 2004. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J. Immunol. 172: 2352-2359. https://doi.org/10.4049/jimmunol.172.4.2352
- Xu, H., I. Y. Cheung, H. F. Guo, and N. K. Cheung. 2009. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 69: 6275-6281. https://doi.org/10.1158/0008-5472.CAN-08-4517
- Chen, C., Y. Shen, Q. X. Qu, X. Q. Chen, X. G. Zhang, and J. A. Huang. 2013. Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response. Exp. Cell Res. 319: 96-102. https://doi.org/10.1016/j.yexcr.2012.09.006
- Zhao, X., D. C. Li, X. G. Zhu, W. J. Gan, Z. Li, F. Xiong, Z. X. Zhang, G. B. Zhang, X. G. Zhang, and H. Zhao. 2013. B7-H3 overexpression in pancreatic cancer promotes tumor progression. Int. J. Mol. Med. 31: 283-291. https://doi.org/10.3892/ijmm.2012.1212
- Zhang, G., J. Hou, J. Shi, G. Yu, B. Lu, and X. Zhang. 2008. Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology 123: 538-546. https://doi.org/10.1111/j.1365-2567.2007.02723.x
- Chen, X., G. Zhang, Y. Li, X. Feng, F. Wan, L. Zhang, J. Wang, and X. Zhang. 2009. Circulating B7-H3(CD276) elevations in cerebrospinal fluid and plasma of children with bacterial meningitis. J. Mol. Neurosci. 37: 86-94. https://doi.org/10.1007/s12031-008-9133-z
- Zhang, G., J. Wang, J. Kelly, G. Gu, J. Hou, Y. Zhou, H. P. Redmond, J. H. Wang, and X. Zhang. 2010. B7-H3 augments the inflammatory response and is associated with human sepsis. J. Immunol. 185: 3677-3684. https://doi.org/10.4049/jimmunol.0904020
- Hashiguchi, M., H. Kobori, P. Ritprajak, Y. Kamimura, H. Kozono, and M. Azuma. 2008. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc. Natl. Acad. Sci. USA 105: 10495-10500. https://doi.org/10.1073/pnas.0802423105
- Brunner, A., S. Hinterholzer, P. Riss, G. Heinze, and H. Brustmann. 2012. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis. Gynecol. Oncol. 124: 105-111. https://doi.org/10.1016/j.ygyno.2011.09.012
- Sun, J., L. J. Chen, G. B. Zhang, J. T. Jiang, M. Zhu, Y. Tan, H. T. Wang, B. F. Lu, and X. G. Zhang. 2010. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol. Immunother. 59: 1163-1171. https://doi.org/10.1007/s00262-010-0841-1
- Katayama, A., M. Takahara, K. Kishibe, T. Nagato, I. Kunibe, A. Katada, T. Hayashi, and Y. Harabuchi. 2011. Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumor metastasis and prognosis. Int. J. Oncol. 38: 1219-1226.
- Sica, G. L., I. H. Choi, G. Zhu, K. Tamada, S. D. Wang, H. Tamura, A. I. Chapoval, D. B. Flies, J. Bajorath, and L. Chen. 2003. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18: 849-861. https://doi.org/10.1016/S1074-7613(03)00152-3
- Prasad, D. V., S. Richards, X. M. Mai, and C. Dong. 2003. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18: 863-873. https://doi.org/10.1016/S1074-7613(03)00147-X
- Mugler, K. C., M. Singh, B. Tringler, K. C. Torkko, W. Liu, J. Papkoff, and K. R. Shroyer. 2007. B7-h4 expression in a range of breast pathology: correlation with tumor T-cell infiltration. Appl. Immunohistochem. Mol. Morphol. 15: 363-370. https://doi.org/10.1097/01.pai.0000213159.79557.71
- Li, Z. Y., X. H. Zhang, Y. Chen, J. G. Guo, K. Sai, Q. Y. Yang, Z. P. Chen, and Y. G. Mou. 2013. Clinical significance of B7-H4 expression in matched non-small cell lung cancer brain metastases and primary tumors. Onco. Targets Ther. 6: 869-875.
- Zhu, J., B. F. Chu, Y. P. Yang, S. L. Zhang, M. Zhuang, W. J. Lu, and Y. B. Liu. 2013. B7-H4 expression is associated with cancer progression and predicts patient survival in human thyroid cancer. Asian Pac. J. Cancer Prev. 14: 3011-3015. https://doi.org/10.7314/APJCP.2013.14.5.3011
- Fauci, J. M., J. M. Straughn, Jr., S. Ferrone, and D. J. Buchsbaum. 2012. A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecol Oncol. 127: 420-425. https://doi.org/10.1016/j.ygyno.2012.08.017
- Chen, L. J., J. Sun, H. Y. Wu, S. M. Zhou, Y. Tan, M. Tan, B. E. Shan, B. F. Lu, and X. G. Zhang. 2011. B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol. Immunother. 60: 1047-1055. https://doi.org/10.1007/s00262-011-1017-3
- Kryczek, I., L. Zou, P. Rodriguez, G. Zhu, S. Wei, P. Mottram, M. Brumlik, P. Cheng, T. Curiel, L. Myers, A. Lackner, X. Alvarez, A. Ochoa, L. Chen, and W. Zou. 2006. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203: 871-881. https://doi.org/10.1084/jem.20050930
- Zhu, G., M. M. Augustine, T. Azuma, L. Luo, S. Yao, S. Anand, A. C. Rietz, J. Huang, H. Xu, A. S. Flies, S. J. Flies, K. Tamada, M. Colonna, J. M. van Deursen, and L. Chen. 2009. B7-H4-deficient mice display augmented neutrophilmediated innate immunity. Blood 113: 1759-1767. https://doi.org/10.1182/blood-2008-01-133223
- Qian, Y., B. Hong, L. Shen, Z. Wu, H. Yao, and L. Zhang. 2013. B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells. Cell Tissue Res. 353: 139-151. https://doi.org/10.1007/s00441-013-1640-8
- Cheng, L., J. Jiang, R. Gao, S. Wei, F. Nan, S. Li, and B. Kong. 2009. B7-H4 expression promotes tumorigenesis in ovarian cancer. Int. J. Gynecol. Cancer 19: 1481-1486. https://doi.org/10.1111/IGC.0b013e3181ad0fa2
- Zhang, L., H. Wu, D. Lu, G. Li, C. Sun, H. Song, J. Li, T. Zhai, L. Huang, C. Hou, W. Wang, B. Zhou, S. Chen, B. Lu, and X. Zhang. 2013. The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene. In press: http://www. nature.com/onc/journal/vaop/ncurrent/full/onc2012600.
- Wang, L., R. Rubinstein, J. L. Lines, A. Wasiuk, C. Ahonen, Y. Guo, L. F. Lu, D. Gondek, Y. Wang, R. A. Fava, A. Fiser, S. Almo, and R. J. Noelle. 2011. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208: 577-592. https://doi.org/10.1084/jem.20100619
- Ceeraz, S., E. C. Nowak, and R. J. Noelle. 2013. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. In press: http://dx.doi.org/10.1016/j.it. 2013.07.003.
- Sakr, M. A., T. Takino, T. Domoto, H. Nakano, R. W. Wong, M. Sasaki, Y. Nakanuma, and H. Sato. 2010. GI24 enhances tumor invasiveness by regulating cell surface membrane-type 1 matrix metalloproteinase. Cancer Sci. 101: 2368-2374. https://doi.org/10.1111/j.1349-7006.2010.01675.x
- Aloia, L., S. Parisi, L. Fusco, L. Pastore, and T. Russo. 2010. Differentiation of embryonic stem cells 1 (Dies1) is a component of bone morphogenetic protein 4 (BMP4) signaling pathway required for proper differentiation of mouse embryonic stem cells. J. Biol. Chem. 285: 7776-7783. https://doi.org/10.1074/jbc.M109.077156
- Brandt, C. S., M. Baratin, E. C. Yi, J. Kennedy, Z. Gao, B. Fox, B. Haldeman, C. D. Ostrander, T. Kaifu, C. Chabannon, A. Moretta, R. West, W. Xu, E. Vivier, and S. D. Levin. 2009. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206: 1495-1503. https://doi.org/10.1084/jem.20090681
- Fiegler, N., S. Textor, A. Arnold, A. Rolle, I. Oehme, K. Breuhahn, G. Moldenhauer, M. Witzens-Harig, and A. Cerwenka. 2013. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 122: 684-693. https://doi.org/10.1182/blood-2013-02-482513
- Pogge von Strandmann, E., V. R. Simhadri, B. von Tresckow, S. Sasse, K. S. Reiners, H. P. Hansen, A. Rothe, B. Boll, V. L. Simhadri, P. Borchmann, P. J. McKinnon, M. Hallek, and A. Engert. 2007. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 27: 965-974. https://doi.org/10.1016/j.immuni.2007.10.010
- Sasaki, T., E. C. Gan, A. Wakeham, S. Kornbluth, T. W. Mak, and H. Okada. 2007. HLA-B-associated transcript 3 (Bat3)/ Scythe is essential for p300-mediated acetylation of p53. Genes. Dev. 21: 848-861. https://doi.org/10.1101/gad.1534107
- Correia, D. V., M. Fogli, K. Hudspeth, M. G. da Silva, D. Mavilio, and B. Silva-Santos. 2011. Differentiation of human peripheral blood Vdelta1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 118: 992-1001. https://doi.org/10.1182/blood-2011-02-339135
- Delahaye, N. F., S. Rusakiewicz, I. Martins, C. Menard, S. Roux, L. Lyonnet, P. Paul, M. Sarabi, N. Chaput, M. Semeraro, V. Minard-Colin, V. Poirier-Colame, K. Chaba, C. Flament, V. Baud, H. Authier, S. Kerdine-Romer, M. Pallardy, I. Cremer, L. Peaudecerf, B. Rocha, D. Valteau-Couanet, J. C. Gutierrez, J. A. Nunes, F. Commo, S. Bonvalot, N. Ibrahim, P. Terrier, P. Opolon, C. Bottino, A. Moretta, J. Tavernier, P. Rihet, J. M. Coindre, J. Y. Blay, N. Isambert, J. F. Emile, E. Vivier, A. Lecesne, G. Kroemer, and L. Zitvogel. 2011. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat. Med. 17: 700-707. https://doi.org/10.1038/nm.2366
- Mager, D. L., D. G. Hunter, M. Schertzer, and J. D. Freeman. 1999. Endogenous retroviruses provide the primary polyadenylation signal for two new human genes (HHLA2 and HHLA3). Genomics 59: 255-263. https://doi.org/10.1006/geno.1999.5877
- Flajnik, M. F., T. Tlapakova, M. F. Criscitiello, V. Krylov, and Y. Ohta. 2012. Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC. Immunogenetics 64: 571-590. https://doi.org/10.1007/s00251-012-0616-2
- Zhu, Y., S. Yao, B. P. Iliopoulou, X. Han, M. M. Augustine, H. Xu, R. T. Phennicie, S. J. Flies, M. Broadwater, W. Ruff, J. M. Taube, L. Zheng, L. Luo, G. Zhu, J. Chen, and L. Chen. 2013. B7-H5 costimulates human T cells via CD28H. Nat. Commun. 4: 2043.
Cited by
- T Lymphocyte Antigen 4-Modified Dendritic Cell Therapy for Asthmatic Mice Guided by the CCR7 Chemokine Receptor vol.15, pp.9, 2013, https://doi.org/10.3390/ijms150915304
- Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer vol.5, pp.8, 2013, https://doi.org/10.1080/2162402x.2016.1207841
- The immune molecular landscape of the B7 and TNFR immunoregulatory ligand–receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications vol.6, pp.3, 2017, https://doi.org/10.1080/2162402x.2017.1288329
- Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies vol.18, pp.14, 2013, https://doi.org/10.1080/14656566.2017.1369956
- PD-1 related transcriptome profile and clinical outcome in diffuse gliomas vol.7, pp.2, 2013, https://doi.org/10.1080/2162402x.2017.1382792
- The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability vol.7, pp.10, 2013, https://doi.org/10.1080/2162402x.2018.1488566
- Disruption of the Epidermal Barrier Induces Regulatory T Cells via IL-33 in Mice vol.138, pp.3, 2013, https://doi.org/10.1016/j.jid.2017.09.032
- Lessons learned from the blockade of immune checkpoints in cancer immunotherapy vol.11, pp.1, 2013, https://doi.org/10.1186/s13045-018-0578-4
- The essential role of costimulatory molecules in systemic lupus erythematosus vol.28, pp.5, 2013, https://doi.org/10.1177/0961203319829818
- PD-L1 status in breast cancer vol.81, pp.2, 2013, https://doi.org/10.17116/patol2019810213
- Inhibition of immune checkpoints prevents injury-induced heterotopic ossification vol.7, pp.1, 2013, https://doi.org/10.1038/s41413-019-0074-7
- Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets vol.69, pp.7, 2013, https://doi.org/10.1007/s00262-020-02530-x
- B7-H3 Immune Checkpoint Protein in Human Cancer vol.27, pp.24, 2013, https://doi.org/10.2174/0929867326666190517115515
- Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer vol.15, pp.4, 2020, https://doi.org/10.1007/s11523-020-00730-0
- The nature of triple-negative breast cancer classification and antitumoral strategies vol.18, pp.4, 2013, https://doi.org/10.5808/gi.2020.18.4.e35
- PD-L1 Glycosylation and Its Impact on Binding to Clinical Antibodies vol.20, pp.1, 2013, https://doi.org/10.1021/acs.jproteome.0c00521
- Cancer Vaccines, Adjuvants, and Delivery Systems vol.12, pp.None, 2013, https://doi.org/10.3389/fimmu.2021.627932
- B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling vol.18, pp.6, 2013, https://doi.org/10.1038/s41423-020-0361-7